Evidence map›Paper›PMID 40361341›Full record

ReviewCancers2025

Treatment Sequencing in Metastatic HR+/HER2- Breast Cancer: A Delphi Consensus.

Lazar Popović, Simona Borštnar, Ivana Božović-Spasojević, Ana Cvetanović, Natalija Dedić Plavetić, Radka Kaneva, Assia Konsoulova, Erika Matos, Snježana Tomić, Eduard Vrdoljak

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. AMCP Market Insights: Managed care approaches toJournal of managed care & specialty pharmacy · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lazar PopovićOncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.ORCID 0000-0002-3278-6875
Simona BorštnarInstitute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Ivana Božović-SpasojevićInstitute for Oncology and Radiology of Serbia, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.
Ana CvetanovićUniversity Clinical Centre Niš, Medical Faculty of Niš, 18000 Niš, Serbia.
Natalija Dedić PlavetićUniversity Clinical Hospital Center Zagreb, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0003-0505-4756
Radka KanevaMolecular Medicine Center, Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0002-1437-1393
Assia KonsoulovaUniversity Cancer Hospital Prof. Ivan Chernozemski, 1756 Sofia, Bulgaria.
Erika MatosInstitute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0001-5144-1285
Snježana TomićClinical Hospital Center Split, University of Split School of Medicine, 21000 Split, Croatia.
Eduard VrdoljakClinical Hospital Center Split, University of Split School of Medicine, 21000 Split, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Delphi consensusHR+/HER2− metastatic breast cancersecond-line therapytargeted therapytreatment choice

Identifiers

PMID40361341
PMCPMC12070964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.